⌕
AbCellera Biologics · ABCL · Nasdaq
Tenet 49 · Mixed
Compare
$11.03−0.81%At closeTenet 49 · Mixed
$11.03−0.09 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AbCellera Biologics (ABCL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

46 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 85% below its peak, net margin −194.9%.
The four lines that matter · FY21–FY25
Revenue ($M)▲160.6%
75.1
FY21→FY25CAGR −33.1%/yr
Net income ($M)▲10.1%
−146.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲6.9%
−174.1
FY21→FY25CAGR —
Diluted EPS▲10.9%
−0.49
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−6.2%

318.3mn → 298.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$42.8M

−45.4% YoY in FY25 · 56.9% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)75.1Revenue0.0COGS−186.8R&D−83.2SG&A−217.1Op income70.7Tax & other−146.4Net income

-195¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -194.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
67.975.128.838.0485.4375.2▲160.6%−33.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A375.2——
Research & development
186.3186.8167.3175.7107.962.1▲11.7%+31.7%
Selling, general & admin
57.083.285.575.255.541.8▼2.6%+18.8%
Total operating expenses
270.0292.2343.6275.2268.9170.8▼14.9%+14.4%
Operating incomefeeds ROC rank
−202.2−217.1−314.8−237.2216.5204.4▲31.0%—
Other income, net
31.439.5114.463.222.614.7——
Pretax income
−170.8−177.6−200.4−174.0239.1219.1▲11.4%—
Income tax
−22.5−31.2−37.5−27.680.665.7▲16.9%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−148.3−146.4−162.9−146.4158.5153.5▲10.1%—
Per share
Diluted EPSbuyback-sensitive
−0.48−0.49−0.55−0.510.500.48▲10.9%—
Diluted shares (mn)
318.05298.71294.33289.17314.83318.29▲1.5%−1.6%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−298.0%−289.0%−1091.7%−623.8%44.6%54.5%▲802.7pp−343.5pp
Net margin7th pct in Healthcare
−218.5%−194.9%−564.8%−385.0%32.7%40.9%▲369.9pp−235.8pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 30% vs a 19% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 34% vs a 19% norm for this window, likely a one-time item; see the filing.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was AbCellera Biologics' revenue last fiscal year?

AbCellera Biologics reported revenue of $75.1M in fiscal 2025, up 160.6% from fiscal 2024.

What was AbCellera Biologics' net income?

AbCellera Biologics reported net income of −$146.4M in fiscal 2025, a net margin of −194.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.